You are in:Home/Publications/Clinico‑serological associations of urinary activated leukocyte cell adhesion molecule in systemic lupus erythematosus and lupus nephritis

Dr. Dalia Mohamed AbdElhaseeb Ahmed :: Publications:

Title:
Clinico‑serological associations of urinary activated leukocyte cell adhesion molecule in systemic lupus erythematosus and lupus nephritis
Authors: Arwa S. Amer1 · Samia M. Abdel moneam1 · Nashwa I. Hashaad1 · Eman M. Yousef1 · Dalia M. Abd El‑Hassib2
Year: 2024
Keywords: Not Available
Journal: Not Available
Volume: Not Available
Issue: Not Available
Pages: Not Available
Publisher: Not Available
Local/International: Local
Paper Link: Not Available
Full paper Dalia Mohamed AbdElhaseeb Ahmed_7s10067-024-06883-x.pdf
Supplementary materials Not Available
Abstract:

Background Lupus nephritis (LN) is one of the major complications associated with Systemic Lupus Erythematosus (SLE). Activated leukocyte cell adhesion molecule (ALCAM or CD166) is a promising urine biomarker that binds to CD6, a receptor found on lymphocytes. This binding results in T-cell activation, proliferation, and recruitment, which causes tissue infammation and may explain the pathophysiology of LN. Aim of work Investigate the urinary ALCAM level in SLE, study its relationship to disease activity, and clarify the association with LN activity and histopathology. Patients and methods A case–control study was performed on 60 patients with SLE and 20 matched controls. The SLE disease activity index (SLEDAI) and the activity of renal disease (rSLEDAI) were evaluated. Renal biopsy and uALCAM levels were also investigated. Results Urinary ALCAM levels were higher signifcantly in active LN patients than inactive LN patients, active and inactive non-LN SLE, and the control group (p

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus